# Cellectar Biosciences, Inc.: overview CLRB · Nasdaq · CIK 1279704 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/clrb.md) · [Financials](/companies/clrb/financials.md) · [Filings](/companies/clrb/filings.md) · [Insiders](/companies/clrb/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(12.13)](/filings/0001104659-25-110827.md) | not reported | [(4.30)](/filings/0001104659-26-060678.md) | [(3.39)](/filings/0001104659-26-095426.md) | [(1.41)](/filings/0001104659-25-110827.md) | not reported | [(1.33)](/filings/0001104659-26-060678.md) | [(0.57)](/filings/0001104659-26-095426.md) | | Free cash flow | $m | [(9.2) d](/filings/0001104659-25-110827.md) | [(11.0) d](/filings/0001104659-26-023167.md) | not reported | not reported | not reported | not reported | [(4.8)](/filings/0001104659-26-060678.md) | [(6.0) d](/filings/0001104659-26-095426.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(4.35)](/filings/0001410578-23-000224.md) | [(4.51)](/filings/0001410578-24-001704.md) | [(3.50)](/filings/0001410578-25-000329.md) | [(41.89)](/filings/0001104659-26-023167.md) | [(8.35)](/filings/0001104659-26-023167.md) | | Free cash flow | $m | [(22.7)](/filings/0001410578-23-000224.md) | [(25.4)](/filings/0001410578-24-001704.md) | [(33.2)](/filings/0001410578-25-000329.md) | [(47.7)](/filings/0001104659-26-023167.md) | [(23.1)](/filings/0001104659-26-023167.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/clrb/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Caligan Partners LP](/funds/1727492.md) | 2026-06-30 | $1.3m | 469,998 | | New +469,998 | | [STEMPOINT CAPITAL LP](/funds/1952142.md) | 2026-06-30 | $986.7k | 354,938 | | New +354,938 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $910.1k | 327,367 | | Added +245,483 | | [SILVERARC CAPITAL MANAGEMENT, LLC](/funds/1816307.md) | 2026-06-30 | $894.4k | 321,728 | | New +321,728 | | [Bleichroeder LP](/funds/1781002.md) | 2026-06-30 | $802.5k | 288,679 | | Added +188,679 | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $759.4k | 274,156 | | Not compared | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $611.6k | 220,000 | | New +220,000 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $611.6k | 219,998 | | New +219,998 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $611.6k | 219,998 | | New +219,998 | | [Empery Asset Management, LP](/funds/1469336.md) | 2026-06-30 | $527.1k | 189,605 | | New +189,605 | ## Recent filings [All 1,099 filings](/companies/clrb/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-13 | 07:25 ET | [8-K](/filings/0001104659-26-095460.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-095460 | | 2026-08-13 | 07:00 ET | [10-Q](/filings/0001104659-26-095426.md) | Quarterly report, period 2026-06-30 | 0001104659-26-095426 | | 2026-07-10 | 17:13 ET | [8-K](/filings/0001104659-26-082719.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-082719 | | 2026-05-29 | 08:50 ET | [S-1/A](/filings/0001104659-26-067933.md) | Registration statement, amended | 0001104659-26-067933 | | 2026-05-28 | 17:13 ET | [DEF 14A](/filings/0001104659-26-067626.md) | Proxy statement, period 2026-07-07 | 0001104659-26-067626 | | 2026-05-19 | 17:05 ET | [S-1](/filings/0001104659-26-063918.md) | Registration statement | 0001104659-26-063918 | | 2026-05-18 | 16:15 ET | [8-K](/filings/0001104659-26-063202.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-063202 | | 2026-05-14 | 07:20 ET | [8-K](/filings/0001104659-26-060693.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-060693 | | 2026-05-14 | 07:00 ET | [10-Q](/filings/0001104659-26-060678.md) | Quarterly report, period 2026-03-31 | 0001104659-26-060678 | | 2026-05-08 | 06:04 ET | [8-K](/filings/0001104659-26-057460.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-057460 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-023167.md), filed Mar 4, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1279704 - Tickers: CLRB - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.